{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.1","upperLimit":"24.0","value":"12.3"},{"groupId":"OG001","lowerLimit":"12.0","upperLimit":"12.3","value":"12.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"49"}],"units":"Participants"}],"description":"MCyR was categorized as either CCyR or PCyR. CCyR was achieved when there was 0% Ph+ cells from at least 20 metaphases from conventional bone marrow cytogenetics or \\<1% positive cells from at least 200 cells analyzed from FISH. PCyR was achieved when 1 to 35% Ph+ cells were present. Time to MCyR was the interval from the date of first dose of study medication until the first date of achieving a given response.\n\nTime to response in weeks equals (=) (event date minus (-) first dose date plus (+) 1)divided (/)7, where the event date is the non-missing date of the first attained response for responders only.","dispersionType":"95% Confidence Interval","groups":[{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP2L IM-R CML; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.","id":"OG000","title":"Bosutinib 500 mg, CP2L-CML IM-R (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP2L IM-I CML; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.","id":"OG001","title":"Bosutinib 500 mg, CP2L-CML IM-I (Part 2)"}],"paramType":"MEDIAN","populationDescription":"Cytogenetic evaluable population included all enrolled participants who received at least one dose of study medication and had an adequate baseline cytogenetic assessment.","reportingStatus":"POSTED","timeFrame":"Week 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks thereafter up to Year 5","title":"Time to Achieve Major Cytogenetic Response (MCyR) in Chronic Phase Second-line CML for Responders Only - Part 2","type":"SECONDARY","unitOfMeasure":"weeks"}